Form 8-K - Current report:
SEC Accession No. 0001104659-21-043908
Filing Date
2021-03-30
Accepted
2021-03-30 16:43:24
Documents
5
Period of Report
2021-03-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2111326d1_8k.htm 8-K 24177
2 EXHIBIT 3.1 tm2111326d1_ex3-1.htm EX-3.1 33792
3 EXHIBIT 3.2 tm2111326d1_ex3-2.htm EX-3.2 202902
4 EXHIBIT 99.1 tm2111326d1_ex99-1.htm EX-99.1 6199
5 GRAPHIC tm2111326d1_ex99-1img01.jpg GRAPHIC 7600
  Complete submission text file 0001104659-21-043908.txt   278964
Mailing Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022
Business Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022 212-739-6451
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 21786509
SIC: 2834 Pharmaceutical Preparations